Q2 2025 Vistin Pharma ASA Earnings Call Transcript
Key Points
- Vistin Pharma ASA (FRA:VP4) reported an 11% increase in revenue for Q2 2025, reaching NOK118 million compared to NOK106 million in the same quarter last year.
- The company achieved a 17% increase in sales volumes compared to the same quarter last year, contributing to the revenue growth.
- EBITDA for Q2 2025 increased by 11% to NOK30 million, driven by higher sales volumes and cost improvements.
- Vistin Pharma ASA has a strong market position as a leading global producer of premium quality metformin, with a market share of approximately 10%.
- The company benefits from a long-term renewable energy supply agreement with Statkraft, ensuring predictable power prices and 100% green renewable hydro power until 2032.
- The company faces volatile freight lead times from Asia to Europe, although it currently maintains safety stock to mitigate production impacts.
- Net profit for the period slightly decreased to NOK18.5 million compared to NOK19 million in the same quarter last year.
- There is an increase in working capital due to higher inventory levels, driven by volatile lead times and the need for safety stock.
- The company has a net debt of NOK40 million as of the end of June, influenced by dividend payouts and increased working capital.
- Growth is limited by the ramp-up of manufacturing capacity, with technical challenges expected in achieving the target of 7,000 metric tons of production.
Good day, and thank you for standing by. Welcome to the Vistin Pharma Quarterly Report Q2 2025 Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Magnus Tolleshaug, CEO. Please go ahead.
Thank you very much, and welcome all to this second quarter and year-to-date presentation of Vistin Pharma. My name is Magnus Tolleshaug, CEO of the company. And with me today, I have our CFO, Mr. Alexander Karlsen. I will now go through the highlights. The revenue in the second quarter ended at NOK118 million compared to NOK106 million in the second quarter last year, an increase of 11%.
The increased revenue was driven by 17% higher sales volumes compared to same quarter last year. The year-to-date revenue ended at NOK233 million compared to NOK210 million year-to-date last year, an increase of 11%. The EBITDA at the second quarter ended at NOK30 million compared to NOK27
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
